Format

Send to

Choose Destination
Diab Vasc Dis Res. 2015 Mar;12(2):101-10. doi: 10.1177/1479164114563304.

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Author information

1
Lexicon Pharmaceuticals, Inc., Princeton, NJ, USA plapuerta@lxrx.com.
2
Lexicon Pharmaceuticals, Inc., Princeton, NJ, USA.
3
Lexicon Pharmaceuticals, Inc., Princeton, NJ, USA Baylor College of Medicine, Houston, TX, USA.

Abstract

The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes. Development of SGLT2 inhibitors has been oriented around a desire for high selectivity for the SGLT2 protein relative to the SGLT1 protein. More recently, genetic and pharmacology research in mice has indicated that gastrointestinal SGLT1 inhibition may also be an appropriate therapeutic target to treat diabetes. Combining SGLT1 and SGLT2 inhibition in a single molecule would provide complementary insulin-independent mechanisms to treat diabetes. Therefore, sotagliflozin (LX4211) has been developed as a dual inhibitor of SGLT1 and SGLT2. The differentiating clinical features of dual inhibitor of SGLT1 and SGLT2 include a large postprandial glucose reduction, elevation of glucagon-like peptide 1 and modest urinary glucose excretion. These features may have clinical implications for the use of sotagliflozin in the treatment of both type 1 and type 2 diabetes.

KEYWORDS:

LX4211; diabetes mellitus; diabetes mellitus type 2; glucagon-like peptide 1; sodium-glucose transporter 1; sodium-glucose transporter 2; sotagliflozin; type 1

PMID:
25690134
DOI:
10.1177/1479164114563304
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center